Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
02:15pm, Tuesday, 15'th Oct 2024
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
12:55pm, Tuesday, 15'th Oct 2024
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
10:20am, Tuesday, 15'th Oct 2024
GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
07:30am, Tuesday, 15'th Oct 2024
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligen
GSK hails phase III nasal polyps success
02:51am, Monday, 14'th Oct 2024
GSK PLC (LSE:GSK, NYSE:GSK) has shared promising results from two major clinical trials (ANCHOR-1 and ANCHOR-2) testing its new treatment, depemokimab, for people suffering from chronic rhinosinusitis
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
11:46am, Thursday, 10'th Oct 2024
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
GSK: The Worst Is Finally Over (Rating Upgrade)
11:13am, Thursday, 10'th Oct 2024
GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 2024
GSK Zantac settlement a 'clear win', say brokers
08:18am, Thursday, 10'th Oct 2024
GSK PLC (LSE:GSK, NYSE:GSK) US$2.2 billion settlement for 93% of Zantac litigation cases is almost a best-case scenario short of no payment, according to US broker Jefferies. The broker had pencilled
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
07:15am, Thursday, 10'th Oct 2024
GSK (GSK) shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
07:01am, Thursday, 10'th Oct 2024
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US relate
GSK settles vast majority of Zantac claims for $2.2 billion
04:54am, Thursday, 10'th Oct 2024
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn remedy causes cancer
GSK settles US Zantac lawsuit for $2.2bn
02:54am, Thursday, 10'th Oct 2024
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $2.2 billion to settle around 80,000 US lawsuits concerning its heartburn medication Zantac, generically known as ranitidine. The plaintiffs allege
GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits
02:43am, Thursday, 10'th Oct 2024
Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits that claimed its discontinued heartburn
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
06:39pm, Wednesday, 09'th Oct 2024
In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication.
GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac
02:43pm, Wednesday, 09'th Oct 2024
British drugmaker agrees payment to resolve 80,000 cases alleging cancers were linked to drug known generically as ranitidine
